First published 10/3/2026, 12:57:15 AM · Last updated 10/3/2026, 12:57:15 AM

P3.18.38 Phase 3 eVOLVE-Lung02 Trial of Volrustomig + Chemotherapy (CT) vs Pembrolizumab + CT in Metastatic NSCLC With PD-L1 TC <50%

This journal article title describes a Phase 3 trial (eVOLVE-Lung02) comparing Volrustomig plus chemotherapy versus pembrolizumab plus chemotherapy in metastatic non-small cell lung cancer with PD-L1 tumor cell expression <50%. The supplied source did not include results, locations, sample size, or other trial details.

Illustrative image: Representative Ga-68-Trivehexin PET/CT (left) of a 55-year-old woman with lung adenocarcinoma and multiple metastatic lesions (cT2bN3M1c, IVB), compared with F-18-FDG PET/CT. Both images show maximum intensity projections (MIPs). Yellow arrows: Primary tumor (SUVmax: 20.66 for Ga-68-Trivehexin, vs. 12.45 for F-18-FDG). Red arrows: Metastatic lesions including lymph nodes (SUVmax: 23.88 vs 7.44). Blue arrows: Brain metastases (SUVmax: 3.39– 6.85 vs. 9.78–12.89). Green arrows: Liver metastases (SU — Huiqin Wu, Chongjiao Li, Ling Li, Yueli Tian, Zhiwei Xiao, Yiwei Huang, Juan Zhong, Jianying Huang, Qiongrong Chen, Yong He/Wikimedia Commons, CC BY 4.0

Categories: public-health

Generated scores

Scores are based on the cited reporting and use a 1–10 scale. Read the methodology.

Confidence: 4/10How certain the assessment is based on the clarity and evidence in the cited reporting.
Geographic reach: 1/10How widely the event reaches, from a local area (1) to worldwide impact (10).
Global importance: 3/10The event's broader significance, from limited importance (1) to major global importance (10).
Impact magnitude: 3/10The scale or severity of the real-world impact, from minor (1) to extreme (10).
Positivity: 5/10How harmful or beneficial the event is, from strongly harmful (1) to strongly positive (10).
Urgency: 2/10How time-sensitive the event is, from low urgency (1) to immediate attention needed (10).

Why it matters

The article concerns a Phase 3 clinical trial comparing treatment regimens for metastatic NSCLC patients with PD-L1 TC <50%.

Sources

P3.18.38 Phase 3 eVOLVE-Lung02 Trial of Volrustomig + Chemotherapy (CT) vs Pembrolizumab + CT in Metastatic NSCLC With PD-L1 TC <50%

Report an issue